Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Listeria monocytogenes infection in Crohn's disease treated with adalimumab.

Willson KJ, Jacob A, Shetti MP, Bhatia R, Yee K, Osler W.

Med J Aust. 2012 Oct 15;197(8):466-7. No abstract available.

PMID:
23072245
2.

Treating Crohn's disease: at "deep" remission and exploring beyond.

Corte C, Selby WS.

Med J Aust. 2012 Oct 15;197(8):430-1. No abstract available.

PMID:
23072227
3.

Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.

Petitpain N, Bornert-Keller N, Peyrin-Biroulet L.

J Crohns Colitis. 2013 Oct;7(9):e396. doi: 10.1016/j.crohns.2013.02.011. Epub 2013 Mar 21. No abstract available.

PMID:
23523265
4.
5.

Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy.

Ramos JM, García-Sepulcre MF, Masiá M, Brotons A, Grau MC, Gutiérrez F.

Rev Esp Enferm Dig. 2010 Oct;102(10):614-6. No abstract available.

6.

Commentary: infliximab or adalimumab in Crohn's disease?

Sprakes MB, Hamlin PJ.

Aliment Pharmacol Ther. 2012 Aug;36(4):398. doi: 10.1111/j.1365-2036.2012.05167.x. No abstract available.

7.

Sarcoidosis complicating treatment with adalimumab for Crohn's disease.

McDonnell MJ, Rutherford RM, O'Regan A.

J Crohns Colitis. 2014 Sep;8(9):1140-1. doi: 10.1016/j.crohns.2014.02.006. Epub 2014 Mar 13. No abstract available.

PMID:
24631310
8.

Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?

Lopez-Sanroman A, Gisbert JP.

Aliment Pharmacol Ther. 2012 Sep;36(5):498-9. doi: 10.1111/j.1365-2036.2012.05185.x. No abstract available.

9.

Adalimumab-induced psoriasis in a patient with Crohn's disease.

Korkmaz U, Duman AE, Dindar G, Yilmaz H, Dursun IH, Celebi A, Senturk O, Hulagu S.

Indian J Gastroenterol. 2013 Mar;32(2):135-6. doi: 10.1007/s12664-012-0281-2. No abstract available.

PMID:
23151897
10.

Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?

Tursi A, Elisei W, Picchio M, Penna A.

Aliment Pharmacol Ther. 2013 Apr;37(7):763-4. doi: 10.1111/apt.12238. No abstract available.

11.

A case of adalimumab-induced pneumonitis in a 45-year-old man with Crohn's disease.

Reid JD, Bressler B, English J.

Can Respir J. 2011 Sep-Oct;18(5):262-4.

12.

TNF-α inhibitor (adalimumab) induced psoriasis: a case report.

Al-Mutairi A, Elkashlan M, Al-Fayed HM, Swayed M.

Australas J Dermatol. 2012 May;53(2):157. doi: 10.1111/j.1440-0960.2012.00890.x. No abstract available.

PMID:
22571571
13.

[Efficacy and safety of Adalimumab in Crohn's disease].

Serghini M, Haddad W, Jeddi H, Karoui S, Ben Mustapha N, Kallel L, Fekih M, Matri S, Boubaker J, Filali A.

Tunis Med. 2012 Feb;90(2):101-7. Review. French.

14.

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.

Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, Ascolani M, Pallone F, Biancone L.

Aliment Pharmacol Ther. 2012 Jun;35(12):1397-407. doi: 10.1111/j.1365-2036.2012.05100.x. Epub 2012 Apr 22.

15.

Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.

Mañosa M, Domènech E, Marín L, Olivé A, Zabana Y, Cabré E, Gassull MA.

Gut. 2008 Apr;57(4):559; author reply 559-60. No abstract available.

PMID:
18334664
16.

First case report of adalimumab-induced psoriasis in Crohn's disease.

Harris MD, Richards R.

Am J Gastroenterol. 2009 Mar;104(3):792-3. doi: 10.1038/ajg.2008.101. Epub 2009 Feb 3. No abstract available.

PMID:
19262532
17.

Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.

Cesarini M, Angelucci E, Foglietta T, Vernia P.

J Crohns Colitis. 2011 Dec;5(6):619-22. doi: 10.1016/j.crohns.2011.06.010. Epub 2011 Jul 28. Review.

PMID:
22115384
18.

Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease.

Jordan N, Waghmare A, Abi-Ghanem AS, Moon A, Salvatore CM.

J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):294-6. doi: 10.1097/MPG.0b013e31822938c3. No abstract available.

PMID:
21694635
19.

Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.

Emmert MY, Salzberg SP, Emmert LS, Behjati S, Plass A, Felix C, Falk V, Gruenenfelder J.

Eur J Heart Fail. 2009 Nov;11(11):1106-9. doi: 10.1093/eurjhf/hfp132.

20.

[Adalimumab in Crohn's disease - data from real life].

López San Román A, Van Domselaar M, Garrido E.

Rev Esp Enferm Dig. 2008 Nov;100(11):671-5. Spanish. No abstract available.

Supplemental Content

Support Center